2186 Stock Overview
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2186 from our risk checks.
Luye Pharma Group Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.86 |
52 Week High | HK$4.05 |
52 Week Low | HK$2.34 |
Beta | 0.82 |
1 Month Change | 4.00% |
3 Month Change | -19.89% |
1 Year Change | -16.13% |
3 Year Change | -43.37% |
5 Year Change | -60.00% |
Change since IPO | -42.91% |
Recent News & Updates
Recent updates
Shareholder Returns
2186 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | -2.4% | -2.3% | -1.2% |
1Y | -16.1% | -11.9% | -12.2% |
Return vs Industry: 2186 underperformed the Hong Kong Pharmaceuticals industry which returned -11.9% over the past year.
Return vs Market: 2186 underperformed the Hong Kong Market which returned -12.2% over the past year.
Price Volatility
2186 volatility | |
---|---|
2186 Average Weekly Movement | 7.0% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 7.3% |
10% most volatile stocks in HK Market | 14.7% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2186's share price has been volatile over the past 3 months.
Volatility Over Time: 2186's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 5,005 | Dian Bo Liu | https://www.luye.cn |
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer’s disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders.
Luye Pharma Group Ltd. Fundamentals Summary
2186 fundamental statistics | |
---|---|
Market cap | HK$10.76b |
Earnings (TTM) | HK$496.16m |
Revenue (TTM) | HK$6.54b |
21.5x
P/E Ratio1.6x
P/S RatioIs 2186 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2186 income statement (TTM) | |
---|---|
Revenue | CN¥6.03b |
Cost of Revenue | CN¥2.00b |
Gross Profit | CN¥4.03b |
Other Expenses | CN¥3.58b |
Earnings | CN¥457.79m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 27, 2024
Earnings per share (EPS) | 0.12 |
Gross Margin | 66.84% |
Net Profit Margin | 7.59% |
Debt/Equity Ratio | 80.7% |
How did 2186 perform over the long term?
See historical performance and comparison